Table 2 Estimates of effectiveness (95% CIs)

From: Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia

 

Omicron predicted effectiveness

 

BNT162b2 (2 dose)

mRNA boosted

Symptomatic

40.8% (25.9%–55.0%)

77.3% (65.1%–86.1%)

Severe*

81.4% (50.9%–94.8%)

96.4% (84.8%–99.3%)

  1. *Vaccine effectiveness against severe outcomes is much less well-validated as there is insufficient data available with which to parameterize the model at such low titres against severe outcomes, in addition to a lack of understanding of baseline severity with Omicron.
Back to article page